ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented At ASCO

June 3, 2009

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced the presentation of encouraging trastuzumab-DM1 (T-DM1) clinical data at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Orlando, Florida.

T-DM1, an antibody-drug conjugate, consists of ImmunoGen’s DM1 cancer-cell killing agent linked to the HER2-targeted antibody, trastuzumab, developed by Genentech, Inc. (a wholly-owned member of the Roche Group). Genentech (US) and Roche (ex-US) are conducting a broad clinical program with T-DM1 in HER2-positive breast cancer.
Read the rest of this entry »


London Professor Wins Clinical Psychology Award, UK

June 2, 2009

Professor Til Wykes is to receive the 2009 M.B. Shapiro Award from the British Psychological Society’s Division of Clinical Psychology. It is the Division’s premier award and is made each year to a clinical psychologist who has achieved eminence in the profession.

Professor Wykes will give her Award Lecture at the Division of Clinical Psychology’s Annual Conference, to be held at the Congress Centre, 28 Great Russell Street, London WC1, on 9-11 December 2009. Further information about the Conference can be found at
Read the rest of this entry »

Zetiq Reports Success In Clinical Trial Aimed For Early Identification Of Cervical Cancer

May 28, 2009

Zetiq, a subsidiary of Bio-Light Ltd. (TASE:BOLT), reports the successful completion of a clinical trial to validate feasibility of early identification of cervical cancer.

The trial was conducted on cervical smears collected from 74 subjects at Meir MC and Macabbi health services in Israel. The collected samples were processed with the advanced liquid based cytology method, and examined using 3 methods: staining with the traditional widely used Pap method, testing to identify the presence of the HPV virus that causes the disease, and staining with the Zetiq method. The analysis of the specimens was conducted by the company’s team as well as by an independent professional.
Read the rest of this entry »

Medimix International To Exhibit At American Society of Clinical Oncology AGM

May 27, 2009

Medimix International, a leader in global healthcare marketing research for life sciences industry, announced that it will be exhibiting at the 45th AGM of the American Society of Clinical Oncology, which will take place in Orlando, Florida from May 29-June 2, 2009. The annual ASCO meeting is considered to be the premier educational and scientific event in the oncology community, a forum for cutting-edge scientific and educational developments in oncology with a focus on personalizing cancer care.
Read the rest of this entry »

Emergency Physicians Don’t Follow Established Clinical Guidelines For Diagnosing Patients With Possible Pulmonary Emboli

May 24, 2009

The number of MDCT examinations for suspected pulmonary emboli (PE) is rapidly increasing amongst ER patients, with a decrease in the number of positive studies. This may be due to a failure to adhere to established clinical guidelines for evaluating patients with suspected PE, according to a study performed at the Warren Alpert Medical School of Brown University and Rhode Island Hospital, Providence, RI.

Current accepted clinical practice indicates that patients with a low clinical suspicion for PE should undergo D-dimer testing, then MDCT if positive. A total of 5,344 patients were reviewed. “42% of patients had a positive D-dimer exam and did not have a CT scan. Current protocols suggest that those patients should have had a scan,” said Michael T. Corwin, MD, lead author of the study. “MDCT was performed in 7% of patients with negative D-dimer results, and the same protocols suggest that those patients should not have undergone a scan,” said Dr. Corwin
Read the rest of this entry »

NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results To Taxus(R) Liberte(R) Stent In Pivotal Clinical Trial

May 23, 2009

At six months, the NEVO™ Sirolimus-eluting Coronary Stent, incorporating RES Technology™, was superior to the Taxus Liberte Stent in reducing tissue growth within the stent that can potentially lead to repeat procedures, in new clinical study results released . In addition, no reports of stent thrombosis were reported in patients treated with NEVO™ through six months.

The results of the NEVO RES I study comparing these two drug-eluting stents were presented during Late Breaking Clinical Trials at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.
Read the rest of this entry »

Pixantrone Phase 3 Data To Be Presented At The 2009 American Society Of Clinical Oncology (ASCO) Annual Meeting

May 17, 2009

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that data from CTI’s pivotal phase III EXTEND (PIX301) trial of pixantrone in patients with advanced, relapsed aggressive non-Hodgkin’s lymphoma (NHL) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009 in Orlando, Florida.

Ruth Pettengell, M.D. of St. George’s Hospital, University of London, an investigator on the study, is scheduled to present the data on Monday, June 1, 2009 during the Lymphoma and Plasma Cell Disorders session that will be held from 2:00 PM-6:00 PM Eastern Time. The presentation, abstract #8523, is titled, “Randomized Phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin’s lymphoma.”
Read the rest of this entry »